Biointerventional solutions for heart failure, chronic myocardial ischemia, and acute myocardial infarction


Feb 21, 2016
BioCardia®, Inc. Announces Two Presentations Related to Cardiamp Cell Therapy at Cardiovascular Research Technologies in Washington, DC

Jan 28, 2016
BioCardia Announces Upcoming Cell Therapy Presentations at Cardiovascular Research Technologies Conference

Oct 6, 2015
BioCardia to Present at 2015 Stem Cell Meeting on the Mesa

Jun 16, 2015
BioCardia, Inc. Files Registration Statement for Proposed Initial Public Offering

Nov 11, 2014
BioCardia®, Inc. Announces FDA Acceptance of Phase III Clinical Trial Protocol Studying Bone Marrow-Derived Cell Therapy for Heart Failure Patients

Sep 15, 2014
CellProThera® and BioCardia® Partner on Phase II Trial to Study CellProThera’s Protheracytes® CD34+ Cells as Delivered by BioCardia’s Helix™ Transendocardial Delivery System

May 19, 2014
Phase II STOP-HF Trial Shows Excellent Safety Profile, Supports Efficacy for Juventas JVS-100 as Delivered by BioCardia® Helix™ Transendocardial Delivery System

May 7, 2014
RECARDIO Clinical Trial Doses First Patient

March 17, 2014
BioCardia® Receives CE Mark for Morph AccessPro™ Steerable Introducer

more news



We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. BioCardia is developing proprietary comprehensive  biotherapeutic solutions for cardiovascular disease in its CardiAMP™ and CardiALLO™ therapies. Clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. 

These programs are enabled by the Company's Helix transendocardial delivery systems and Morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.